Labopharm pain combo misses main goal in Phase III trial

04/2/2009 | Reuters

A twice-daily painkiller containing tramadol and acetaminophen did not yield a statistically significant difference in terms of pain intensity in a Phase III trial, Labopharm said. The drugmaker said it plans to meet with the FDA to determine the product's future because the results likely diminish the drug's chance of U.S. approval.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX